Dr Marie Preau and colleagues from France studied the specific impact of treatments for chronic Hepatitis C virus, infection on anger expression, and control in adult patients coinfected with HIV, and Hepatitis C virus receiving antiretroviral therapy.
The team of doctors conducted a cross-sectional survey, collecting both clinical, and sociobehavioral data, in 2 French clinical centers among adult patients coinfected with HIV and Hepatitis C virus, in 2005.
|Control of anger was significantly lower among treated patients|
|Journal of Clinical Gastroenterology|
The participants answered a self-administered questionnaire, anonymously.
The questionnaire was aimed at obtaining sociodemographic, clinical and behavioral characteristics including self-reported treatments' side effects, quality of life, and irritability and anger.
Clinical characteristics were obtained from medical records.
The researchers found that among the 139 patients who were receiving antiretroviral therapy at the time of survey, 24 were being treated for their Hepatitis C virus infection.
The patients were treated using either pegylated interferon, and ribavirin or pegylated interferon alone.
The team noted that control of anger was significantly lower among treated patients than among untreated ones.
The doctors found that sociodemographic, and clinical characteristics did not differ significantly between these 2 groups.
Control of angry feelings was significantly correlated with psychologic and social relationship dimensions of quality of life.
Dr Preaus' team concluded, "Treatment of Hepatitis C virus-HIV coinfected patients may require closer monitoring for anger control issues and adjustment of treatment as appropriate."